About
/
Team
Growth Strategy and Operations
Founder & Chief Executive Officer
Nawal is Founder and CEO of Holmusk, bringing more than fifteen years of finance and strategy consulting experience to the helm of the company. Prior to Holmusk, Nawal founded and led HelloPay (a Rocket Internet Venture), and spent time serving global clients at McKinsey & Company and Credit Suisse. Nawal drives the strategic direction of Holmusk, leading from the front with round-the-clock hustle and infectious energy.
Chief Operations Officer / Chief Strategy Officer
Tony is the Chief Operations Officer / Chief Strategy Officer at Holmusk. Tony brings over two decades of scientific and leadership experience to Holmusk, having served as Chief Scientific Officer at Axcella Health and as a partner in McKinsey’s Life Sciences practice.
General Counsel
Holly is General Counsel at Holmusk. Previously, she was Head of Strategic Assets and General Counsel at Drawbridge Health, Inc., where she served on the executive team. Holly began her career as an attorney at Arnold & Porter, LLP, was Professional Staff on the Science and Technology Committee in the U.S. House of Representatives and has been an advisor and counsel to several life science and technology companies. Holly received her BS in Biochemistry and JD from the University of Michigan, and her MBA in Finance and Management from Wharton at the University of Pennsylvania.
VP, Growth Operations
Paul is Vice President of Growth Operations. He has over 12 years of experience in leading health engagements. His focused has been on integrated health, population management, and data analytic solutions across Southeast Asia and the United States. With experience purposely balanced in strategy, analytics and client engagement, he has worked to drive behavioural and structural changes in the way patients interact and participate within the health ecosystems – striving to create better outcomes for individuals and systems delivering care.
VP, Operations & Strategy
Eileen is Vice President of Product Management. She has over 15 years of experience in the software and medical device industries, with a focus on product innovation and product development lifecycle management. Before joining Holmusk, she worked at Stryker, a leading medical device company, where she successfully launched more than 10 Patient Care products, primarily for the North American and European markets. She is also experienced in business process reengineering. She has an Electrical Engineering degree from McGill University and an MBA from IE Business School.
Partnerships and Business Development
Head Of Holmusk Europe
Stefan Suter is Head of Holmusk Europe. He has 2 decades of experience in healthcare industry across Europe and Asia with a deep understanding of healthcare systems. Stefan is the founder of Curo-Health, has worked at Roche and Novartis in finance and market access, heading up market access department Asia, while based in Singapore. Stefan is passionate about patient-centered care and personalized medicine. Bringing together different experiences and working in diverse cultures and environments to solve real-world problems has always been his zest and asset.
VP, Corporate Development
Sonali is Vice President of Corporate Development. Prior to Holmusk, she was Co-Founder and Chief Customer Officer of Patagonia Health. She led and provided strategic direction to sales, product management and customer success teams. She served numerous public health and behavioral health organization clients across the United States.
Director of Healthcare Solutions
Caroline is the Director of Healthcare Solutions. She is a digital health leader with expertise in NHS collaborations. Caroline is leading Holmusk Europe’s healthcare solutions business and brings 20 years of experience working in a variety of NHS, social care and healthcare industry leadership roles at Merck, Abbvie, GSK and Otsuka. Caroline led the creation and development of MaST, a predictive analytics solution to improve mental health care, for which she has been awarded the NHS Innovation Accelerator Fellowship.
Data Science and Engineering
Chief Analytics Officer
Joydeep is Chief Analytics Officer at Holmusk. He drives the overall data and computational strategy and development across Holmusk products and services. He brings over 15 years of experience in pioneering predictive tools for clinical trials, translational research, clinical decision support, and smart medical devices. Prior to Holmusk, Joydeep led the scientific and computational teams at Immunetrics and Bodylogical (PwC DoubleJump Health).
Product
Chief Technology Officer
Subra is Chief Technology Officer at Holmusk. A computer engineer by training, Subra drives our tech strategy and all new product development, and leads all compliance activities related to privacy and security. He is an enthusiastic Haskell evangelist, much to the dismay of people who end up talking to him.
VP, BEHR Product Management
Guru is the Vice President of BEHR Product Management. He leads the product strategy, development and implementation of the EHR platform. Guru brings extensive healthcare product development and implementation experience from his previous roles at Anthem, Inc., Change Healthcare, McKesson Health Solutions and CSC.
Health and Life Sciences
VP, Pharma & Life Sciences Partnerships
Subina is Vice President of Pharma and Life Sciences Partnerships. She has over 10 years of experience in the biopharma, medical device, and global public health sector. She previously worked at the Pharma & Life Sciences Consulting practice at PwC US, leading strategic and business transformation projects in R&D, medical affairs, and commercial operations. Prior to that, she worked as a medical device design engineer at Ethicon Endo-Surgery and MicroCube. Subina is a Biomedical Engineer by training with a MS from the University of Pennsylvania and a BS from the Georgia Institute of Technology.
Scientific Advisor
John is a Scientific Advisor to Holmusk. He is an internationally renowned psychiatrist and was the primary investigator for the STAR*D study, the largest prospective clinical trial of Major Depressive Disorder ever conducted. He is a Professor Emeritus at the Duke-NUS Medical School, and adjunct professor of Psychiatry and Behavioral Sciences at Duke University School of Medicine. He has authored and edited over 10 books and over 600 scientific journal articles.
Strategic Advisor
Amir is a Scientific Advisor to Holmusk. He is a physician scientist, recognized globally as a leading innovator at the intersection of life sciences and technology, and a convener of collaborative high impact forums. He is a board director of both private and publicly traded companies, and advises companies in the life sciences and technology sectors, universities and investment groups.
Strategic Advisor
Anand is a Strategic Advisor to Holmusk. He is a seasoned healthcare executive with 24 years of global drug development experience. An anesthesiologist by training, he qualified as a medical doctor at University College London. He spent 23 years at Quintiles, where he led the company’s expansion into India and subsequently helped build the business in Japan, Brazil and Peru before taking the company public on the NYSE in 2013. Anand went on to lead and grow the merged IQVIA businesses across Asia Pacific. He is a senior advisor to TPG Capital and is Chairman of Novotech Health Holdings.
Scientific Advisor
Christoph U. Correll is Professor of Psychiatry at The Zucker School of Medicine at Hofstra/ Northwell, New York, USA, and also Professor and Chair of the Department of Child and Adolescent Psychiatry, Charité University Medicine, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City. Since 1997, he has been working and conducting research in New York, USA, and since 2017 he is also working in Germany again.
Chair of the Board
Michael is the Chair of the Board. He is Co-Founder and Managing Partner of Ardan Equity, a healthcare enterprise software private equity firm. Michael is Founding Chair of Phreesia (NYSE: PHR). Previously, he was Co-Founder and Managing Partner of Optum Ventures. Michael was Co-Founder and CEO of Humedica and following its acquisition by UnitedHealth Group he broadened his role within UHG as President and CEO of Optum Analytics. He also was CEO of PharMetrics, which was acquired by IMS Health (now IQVIA). Michael received his Bachelor’s Degree in Economics from Brandeis University and an MBA from Harvard Business School.
Board Member
Vijay a Board Member. Vijay began his career in medicine and worked as a doctor for the NHS. He qualified from Guy’s Kings and St. Thomas Medical School in London and holds a MBBS in Medicine and a B.S. in Development Neurobiology. He was previously a health care investment banker at Peel Hunt and Piper Jaffray, looking after listed health care clients as well as undertaking IPO, M&A, private placement and secondary fundraising transactions. He then became a healthcare investor, initially at an IP commercialisation company and a life science VC fund. Vijay has invested in data driven companies targeting respiratory health, complications of diabetes, patient safety, consent and education.
Founder & Chief Executive Officer
Nawal is Founder and CEO of Holmusk, bringing more than fifteen years of finance and strategy consulting experience to the helm of the company. Prior to Holmusk, Nawal founded and led HelloPay (a Rocket Internet Venture), and spent time serving global clients at McKinsey & Company and Credit Suisse. Nawal drives the strategic direction of Holmusk, leading from the front with round-the-clock hustle and infectious energy.
Singapore
New York
London
Basel